Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 142

1.

Severe hepatic failure related to nevirapine treatment.

Cattelan AM, Erne E, Salatino A, Trevenzoli M, Carretta G, Meneghetti F, Cadrobbi P.

Clin Infect Dis. 1999 Aug;29(2):455-6. No abstract available.

PMID:
10476768
2.

Incidence of rash and discontinuation of nevirapine using two different escalating initial doses.

Antón P, Soriano V, Jiménez-Nácher I, Rodriguez-Rosado R, Dona MC, Barreiro PM, González-Lahoz J.

AIDS. 1999 Mar 11;13(4):524-5. No abstract available.

PMID:
10197383
3.

Lipodystrophy associated with nevirapine-containing antiretroviral therapies.

Aldeen T, Wells C, Hay P, Davidson F, Lau R.

AIDS. 1999 May 7;13(7):865-7. No abstract available.

PMID:
10357391
4.

Leukocytopenia due to zidovudine- and nevirapine-containing regimens in elderly patients with HIV infection.

Yamamoto Y, Yasuoka A, Yasuoka C, Genka I, Teruya K, Kikuchi Y, Tachikawa N, Oka S.

Jpn J Infect Dis. 2000 Dec;53(6):244-5. No abstract available.

PMID:
11227023
5.

[Favorable new data for nevirapine. Antiretroviral effect confirmed--and also lipid profile].

[No authors listed]

MMW Fortschr Med. 2004 Apr 26;146 Spec No 1:58-60. German. No abstract available.

PMID:
15373051
6.

[Combined antiretroviral therapy with nevirapine of HIV-infected adults].

Kravchenko AV.

Ter Arkh. 2004;76(11):68-71. Review. Russian. No abstract available.

PMID:
15658542
7.

Stevens-Johnson syndrome in HIV patients treated with nevirapine: two case reports.

Dodi F, Alessandrini A, Camera M, Gaffuri L, Morandi N, Pagano G.

AIDS. 2002 May 24;16(8):1197-8. No abstract available.

PMID:
12004287
8.

Liver toxicity caused by nevirapine.

González de Requena D, Núñez M, Jiménez-Nácher I, Soriano V.

AIDS. 2002 Jan 25;16(2):290-1.

PMID:
11807315
9.

Switch study of nevirapine.

[No authors listed]

AIDS Patient Care STDS. 2000 Dec;14(12):672. No abstract available.

PMID:
11187109
10.

Long-term safety and efficacy of nevirapine, stavudine and lamivudine in a real-world setting.

Shalit P, Farrell P, Lindgren P.

AIDS. 2001 Apr 13;15(6):804-5. No abstract available.

PMID:
11371699
11.

[Reliable effectiveness for years with good long-term tolerance: 10 years nevirapine--a summary].

[No authors listed]

MMW Fortschr Med. 2008 Apr 28;150 Spec No 1:70. German. No abstract available.

PMID:
19024921
12.

DRESS (drug rash with eosinophilia and systemic symptoms) syndrome associated with nevirapine therapy.

Bourezane Y, Salard D, Hoen B, Vandel S, Drobacheff C, Laurent R.

Clin Infect Dis. 1998 Nov;27(5):1321-2. No abstract available.

PMID:
9827291
13.

[Reliability: nevirapine. Highly effective + favorable influence on lipid profile].

[No authors listed]

MMW Fortschr Med. 2005 Apr 25;147 Spec No 1:42-3. German. No abstract available.

PMID:
16385872
14.

Nevirapine-induced neuropsychiatric complications, a class effect of non-nucleoside reverse transcriptase inhibitors?

Morlese JF, Qazi NA, Gazzard BG, Nelson MR.

AIDS. 2002 Sep 6;16(13):1840-1. No abstract available.

PMID:
12218402
15.

Benefits and risks of switching from protease inhibitors to nevirapine with stable background therapy in patients with low or undetectable viral load: a multicentre study.

De Luca A, Baldini F, Cingolani A, Di Giambenedetto S, Zaccarelli M, Tozzi V, Ammassari A, Murri R, Antinori A.

AIDS. 2000 Jul 28;14(11):1655-6. No abstract available.

PMID:
10983653
16.

Hepatotoxicity in HIV-1-infected patients receiving nevirapine-containing antiretroviral therapy.

Martínez E, Blanco JL, Arnaiz JA, Pérez-Cuevas JB, Mocroft A, Cruceta A, Marcos MA, Milinkovic A, García-Viejo MA, Mallolas J, Carné X, Phillips A, Gatell JM.

AIDS. 2001 Jul 6;15(10):1261-8.

PMID:
11426070
17.

A randomized controlled trial investigating the efficacy and safety of switching from a protease inhibitor to nevirapine in patients with undetectable viral load.

Arranz Caso JA, López JC, Santos I, Estrada V, Castilla V, Sanz J, Sanz J, Molina JP, Fernández Guerrero M, Górgolas M.

HIV Med. 2005 Sep;6(5):353-9. Erratum in: HIV Med. 2005 Nov;6(6):426.

18.

Prednisolone does not prevent the occurrence of nevirapine-induced rashes.

Rey D, Partisani M, Krantz V, Kempf G, Nicolle M, de Mautort E, Priester M, Bernard-Henry C, Lang JM.

AIDS. 1999 Nov 12;13(16):2307. No abstract available.

PMID:
10563719
19.

Determinants of nevirapine hypersensitivity and its effect on the association between hepatitis C status and mortality in antiretroviral drug-naive HIV-positive patients.

Phillips E, Gutiérrez S, Jahnke N, Yip B, Lima VD, Hogg RS, Harrigan PR, Montaner JS.

AIDS. 2007 Jul 31;21(12):1561-8.

PMID:
17630551

Supplemental Content

Support Center